Trial Profile
Phase I trial of oral suberoylanilide hydroxamic acid (SAHA) [vorinostat] in patients with advanced leukaemias
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2006
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 23 Jan 2006 New trial record.